OPX Biotechnologies, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
OPX Biotechnologies, Inc. - overview
Established
2007
Location
Boulder, CO, US
Primary Industry
Chemicals
About
OPX Biotechnologies, Inc. specializes in the commercialization of bio-based products, utilizing innovative technologies to develop sustainable solutions for various industries. Founded in 2007 in Boulder, US, OPX Biotechnologies, Inc. focuses on the production of bio-based chemicals and materials.
The company has undergone strategic pivots to enhance its product offerings. In April 2015, it was acquired by Cargill for an undisclosed amount. The latest funding round was a Series D, raising USD 36. 50 mn, led by US Renewables Group, with investments from Altira Group, Braemar Energy Ventures, DBL Partners, Mohr Davidow Ventures, and XSeed.
The total amount raised by the company is USD 36. 50 mn, with a current valuation of USD 152. 006 mn. OPX Biotechnologies, Inc.
offers a range of bio-based products and solutions designed to replace petroleum-based chemicals, contributing to sustainability in the chemical industry. Their product portfolio includes innovative bioprocessing technologies aimed at supplying renewable and sustainable alternatives for various applications, thereby supporting efforts in environmental sustainability across different sectors. OPX Biotechnologies generates revenue through partnerships with Cargill and other businesses in the agricultural sector, focusing on the production of bio-based chemicals. Their revenue model includes collaborations for developing sustainable chemical solutions and supplying these products to various industries, including agriculture, food, and consumer goods.
Moving forward, OPX Biotechnologies plans to leverage recent funding from the Series D round to expedite the development of new bio-based products targeting the agricultural and industrial sectors. The company aims to expand into new geographic markets, particularly in North America and Europe, by 2017. The acquisition by Cargill in 2015 provides additional resources and alignment with Cargill's extensive distribution networks, facilitating a broader reach for OPX's innovative offerings.
Current Investors
Wolfensohn Fund Management, Mohr Davidow Ventures, Braemar Energy Ventures
Primary Industry
Chemicals
Sub Industries
Waste to Energy, Petrochemicals
Website
www.opxbiotechnologies.com
Verticals
Clean Technology
Total Amount Raised
Subscriber access only
OPX Biotechnologies, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | OPX Biotechnologies, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.